par Makenga Bof, Jean Claude 
;Muteba, Daniel;Mansiangi, Paul;Ilunga-Ilunga, Félicien ;Coppieters, Yves
Référence BMC Pharmacology and Toxicology, 20, 1, page (49), 20(1):49. doi: 10.1186/s40360-019-0327-5
Publication Publié, 2019-08-16
;Muteba, Daniel;Mansiangi, Paul;Ilunga-Ilunga, Félicien ;Coppieters, Yves Référence BMC Pharmacology and Toxicology, 20, 1, page (49), 20(1):49. doi: 10.1186/s40360-019-0327-5
Publication Publié, 2019-08-16
Article révisé par les pairs
| Résumé : | The progress of mass, community-directed, treatment with ivermectin (CDTI) for onchocerciasis control was disrupted by severe adverse effects (SAE) in the Democratic Republic of Congo (DRC). The study aimed at determining the frequency of post-CDTI SAE as well as factors associated with the occurrence of SAE. |
